0001213900-15-004323.txt : 20150608 0001213900-15-004323.hdr.sgml : 20150608 20150608073148 ACCESSION NUMBER: 0001213900-15-004323 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150608 FILED AS OF DATE: 20150608 DATE AS OF CHANGE: 20150608 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BiondVax Pharmaceuticals Ltd. CENTRAL INDEX KEY: 0001611747 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1213 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37353 FILM NUMBER: 15917354 BUSINESS ADDRESS: STREET 1: 14 EINSTEIN ST. CITY: NES-ZIONA STATE: L3 ZIP: 74036 BUSINESS PHONE: 972-8-9302529 MAIL ADDRESS: STREET 1: 14 EINSTEIN ST. CITY: NES-ZIONA STATE: L3 ZIP: 74036 6-K 1 f6k060815_biondvaxpharma.htm REPORT OF FOREIGN PRIVATE ISSUER

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

 

For the Month of June 2015

 

001-37353

(Commission File Number)

 

BIONDVAX PHARMACEUTICALS LTD.

(Exact name of Registrant as specified in its charter)

 

14 Einstein St.

Nes Ziona

Israel 74036

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover

Form 20-F or Form 40-F.

 

Form 20-F þ        Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by

Regulation S-T Rule 101(b)(1): ____

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by

Regulation S-T Rule 101(b)(7): ____

 

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes ☐        No þ

 

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-N/A

 

 

 

 
 

 

Below is an English translation (from Hebrew) from an immediate report by BiondVax Pharmaceuticals Ltd. as published on the Tel-Aviv Stock Exchange Ltd. and the Israeli Securities Authority on June 7, 2015, in accordance with the Israeli Security Regulations.

 

Name of holder

 

IBI Investment House Ltd. – Market maker

 

The name in English

 

IBI Investment House Ltd.

 

Type of holder: Market maker

 

ID type: Registration number in the Israel Companies Registrar: 520034356

 

Nationality / country of incorporation or registration: Incorporated in Israel

 

Does the holder serve as the representative for reporting purposes of several shareholders who, jointly with him / her / it, hold corporation securities Yes

 

Are the ordinary shares treasury shares No

 

Security no. on TASE: 1105204

 

Balance in the previous summary report (the amount of securities): 910

 

Change in the amount of securities: +7,970

 

Holder's maximum holding rate of the security during the reported period: 0.02%

 

Holder's minimum holding rate of the security during the reported period: 0.00%

 

 

 

Name of holder

 

IBI Investment House Ltd.

 

The name in English

 

IBI Investment House Ltd.

 

Type of holder: Management companies of mutual investment trust funds

 

ID type: Registration number in the Israel Companies Registrar: 520034356

 

Country of incorporation or registration: Incorporated in Israel

 

Does the holder serve as the representative for reporting purposes of several shareholders who, jointly with him / her / it, hold corporation securities Yes

 

Are the ordinary shares held treasury shares No

 

Security no. on TASE: 11054204

 

Balance in the previous summary report (the amount of securities): 6,607,098

 

Change in the amount of securities: +2,683,659

 

Holder's maximum holding rate of the security during the reported period: 12.17%

 

Holder's minimum holding rate of the security during the reported period: 5.84%

 

2
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  BiondVax Pharmaceuticals Ltd.
     
Date: June 8, 2015 By: /s/ Ron Babecoff
    Ron Babecoff
    Chief Executive Officer

 

 

3